GB202114529D0 - Lentiviral vectors - Google Patents

Lentiviral vectors

Info

Publication number
GB202114529D0
GB202114529D0 GBGB2114529.7A GB202114529A GB202114529D0 GB 202114529 D0 GB202114529 D0 GB 202114529D0 GB 202114529 A GB202114529 A GB 202114529A GB 202114529 D0 GB202114529 D0 GB 202114529D0
Authority
GB
United Kingdom
Prior art keywords
lentiviral vectors
lentiviral
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2114529.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to GBGB2114529.7A priority Critical patent/GB202114529D0/en
Publication of GB202114529D0 publication Critical patent/GB202114529D0/en
Priority to PCT/GB2022/052586 priority patent/WO2023062367A1/en
Priority to US18/699,885 priority patent/US20250034589A1/en
Priority to KR1020247015385A priority patent/KR20240126856A/ko
Priority to CN202280075601.1A priority patent/CN118234868A/zh
Priority to EP24214942.5A priority patent/EP4530355A3/en
Priority to JP2024521765A priority patent/JP2024536908A/ja
Priority to EP22790351.5A priority patent/EP4416296A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB2114529.7A 2021-10-12 2021-10-12 Lentiviral vectors Ceased GB202114529D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB2114529.7A GB202114529D0 (en) 2021-10-12 2021-10-12 Lentiviral vectors
PCT/GB2022/052586 WO2023062367A1 (en) 2021-10-12 2022-10-12 Lentiviral vectors
US18/699,885 US20250034589A1 (en) 2021-10-12 2022-10-12 Lentiviral Vectors
KR1020247015385A KR20240126856A (ko) 2021-10-12 2022-10-12 렌티바이러스 벡터
CN202280075601.1A CN118234868A (zh) 2021-10-12 2022-10-12 慢病毒载体
EP24214942.5A EP4530355A3 (en) 2021-10-12 2022-10-12 Lentiviral vectors
JP2024521765A JP2024536908A (ja) 2021-10-12 2022-10-12 レンチウイルスベクター
EP22790351.5A EP4416296A1 (en) 2021-10-12 2022-10-12 Lentiviral vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2114529.7A GB202114529D0 (en) 2021-10-12 2021-10-12 Lentiviral vectors

Publications (1)

Publication Number Publication Date
GB202114529D0 true GB202114529D0 (en) 2021-11-24

Family

ID=78595195

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2114529.7A Ceased GB202114529D0 (en) 2021-10-12 2021-10-12 Lentiviral vectors

Country Status (7)

Country Link
US (1) US20250034589A1 (enExample)
EP (2) EP4530355A3 (enExample)
JP (1) JP2024536908A (enExample)
KR (1) KR20240126856A (enExample)
CN (1) CN118234868A (enExample)
GB (1) GB202114529D0 (enExample)
WO (1) WO2023062367A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4589007A1 (en) * 2024-01-17 2025-07-23 Revvity Gene Delivery GmbH Production of viral vectors
WO2026038929A1 (ko) * 2024-08-16 2026-02-19 서울대학교산학협력단 Rna 안정성 또는 mrna 번역 증가용 신규 조절 엘리먼트 및 이의 용도
WO2026085234A1 (en) * 2024-10-18 2026-04-23 Modernatx, Inc. 3' untranslated region sequences for extending messenger ribonucleic acids half-life

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (en) 1993-06-04 1994-12-22 The Regents Of The University Of California Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors
WO1998005635A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO1998007859A2 (en) 1996-08-23 1998-02-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998009985A2 (en) 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides and uses thereof
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
WO1999032646A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
WO1999041397A1 (en) 1998-02-17 1999-08-19 Oxford Biomedica (Uk) Limited Anti-viral vectors
US5952199A (en) 1996-05-07 1999-09-14 Genentech, Inc. Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production
WO2000052188A1 (en) 1999-03-03 2000-09-08 Oxford Biomedica (Uk) Limited Packaging cells for retroviral vectors
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
WO2001079518A2 (en) 2000-04-19 2001-10-25 Oxford Biomedica (Uk) Limited Codon optimisation for expression in retrovirus packaging cells
WO2003064665A2 (en) 2002-02-01 2003-08-07 Oxford Biomedica (Uk) Limited Viral vector
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
US20050002907A1 (en) 2000-10-06 2005-01-06 Kyri Mitrophanous Vector system
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
WO2006010834A1 (fr) 2004-06-25 2006-02-02 Centre National De La Recherche Scientifique Lentivirus non integratif et non replicatif, preparation et utilisations
WO2007071994A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Viral vectors
WO2007072056A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Vectors
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
WO2015092440A1 (en) 2013-12-20 2015-06-25 Oxford Biomedica (Uk) Limited Viral vector production system
EP3502260A1 (en) 2017-12-22 2019-06-26 Oxford BioMedica (UK) Limited Retroviral vector
US20190276844A1 (en) 2009-12-04 2019-09-12 Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
WO2021014157A1 (en) 2019-07-23 2021-01-28 Oxford Biomedica (Uk) Limited Enhancing production of lentiviral vectors
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
WO2001085974A2 (en) * 2000-05-12 2001-11-15 University Of Southern California Retroviral vectors comprising an enhanced 3' transcription termination structure
US20060019393A1 (en) * 2003-12-04 2006-01-26 Cannon Paula M Minimal lentiviral vector system
GB202114532D0 (en) * 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (en) 1993-06-04 1994-12-22 The Regents Of The University Of California Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors
US5952199A (en) 1996-05-07 1999-09-14 Genentech, Inc. Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998005635A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO1998007859A2 (en) 1996-08-23 1998-02-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998009985A2 (en) 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides and uses thereof
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
US7056699B2 (en) 1996-10-29 2006-06-06 Oxford Biomedia (Uk) Limited Lentiviral LTR-deleted vector
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US6287814B1 (en) 1997-09-18 2001-09-11 Salk Institute RNA export element and methods of use
WO1999032646A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
WO1999041397A1 (en) 1998-02-17 1999-08-19 Oxford Biomedica (Uk) Limited Anti-viral vectors
WO2000052188A1 (en) 1999-03-03 2000-09-08 Oxford Biomedica (Uk) Limited Packaging cells for retroviral vectors
WO2001079518A2 (en) 2000-04-19 2001-10-25 Oxford Biomedica (Uk) Limited Codon optimisation for expression in retrovirus packaging cells
US20050002907A1 (en) 2000-10-06 2005-01-06 Kyri Mitrophanous Vector system
WO2003064665A2 (en) 2002-02-01 2003-08-07 Oxford Biomedica (Uk) Limited Viral vector
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
WO2006010834A1 (fr) 2004-06-25 2006-02-02 Centre National De La Recherche Scientifique Lentivirus non integratif et non replicatif, preparation et utilisations
WO2007071994A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Viral vectors
WO2007072056A2 (en) 2005-12-22 2007-06-28 Oxford Biomedica (Uk) Limited Vectors
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
US20190276844A1 (en) 2009-12-04 2019-09-12 Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
WO2015092440A1 (en) 2013-12-20 2015-06-25 Oxford Biomedica (Uk) Limited Viral vector production system
EP3502260A1 (en) 2017-12-22 2019-06-26 Oxford BioMedica (UK) Limited Retroviral vector
WO2021014157A1 (en) 2019-07-23 2021-01-28 Oxford Biomedica (Uk) Limited Enhancing production of lentiviral vectors
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors

Non-Patent Citations (102)

* Cited by examiner, † Cited by third party
Title
"NCBI", Database accession no. 23174
"Oligonucleotide Synthesis: A Practical Approach", 1984, IRL PRESS
"Tissue Culture", 1973, ACADEMIC PRESS
ABE ET AL., J VIROL, vol. 72, no. 8, 1998, pages 6356 - 6361
ADAM ET AL., J.VIROL., vol. 65, 1991, pages 4985
ADAMKOO ET AL., VIROLOGY, vol. 186, 1992, pages 669 - 675
ANTONIOU, M.N.SKIPPER, K.A.ANAKOK, O., HUM. GENE THER., vol. 24, 2013, pages 914 - 927
ATSCHUL ET AL., J. MOL. BIOL., 1990, pages 403 - 410
AUSUBEL, F. M. ET AL.: "Current Protocols in Molecular Biology", 1995, JOHN WILEY & SONS
AZAM ET AL., RNA BIOL., vol. 16, 2019, pages 1001 - 1009
B. ROEJ. CRABTREEA. KAHN: "DNA Isolation and Sequencing: Essential Techniques", 1996, JOHN WILEY & SONS
BABITZKE P, Y. J.CAMPANELLI D., JOURNAL OF BACTERIOLOGY, vol. 178, no. 17, 1996, pages 5159 - 5163
BALAGGAN, K.S.ALI, R.R., GENE THER., vol. 19, 2012, pages 145 - 153
BALSANO, C. ET AL., BIOCHEM. BIOPHYS RES. COMMUN., vol. 176, 1991, pages 985 - 92
BATES ET AL., PHARMACOLOGICAL REVIEWS, vol. 69, 2017, pages 63 - 79
BEAUDOING ET AL., GENOME RES., vol. 10, 2000, pages 1001 - 1010
BERKHAUT ET AL., J. MOL. BIOL., vol. 252, 1995, pages 59 - 69
BROWN ET AL., SCIENCE, vol. 368, 2020, pages 413 - 417
BURNS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 8033 - 7
CAPASSO, C. ET AL., VIRUSES, vol. 6, 2014, pages 832 - 855
CAPUTI, M ET AL., J VIROL., vol. 78, no. 12, 2004, pages 6517 - 6526
CHEN ET AL., J. VIROL, vol. 67, 1993, pages 2142 - 2148
CHUNG J HWHITELY MFELSENFELD G, CELL, vol. 74, 1993, pages 505 - 514
COOPER A., R. ET AL., NUCLEIC ACIDS RESEARCH, vol. 43, 9 January 2015 (2015-01-09), pages 682 - 690
COUNE, P.G.SCHNEIDER, B.L.AEBISCHER, P., COLD SPRING HARB. PERSPECT. MED., vol. 4, 2012, pages a009431
D. M. J. LILLEYJ. E. DAHLBERG: "Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology", 1992, ACADEMIC PRESS
DANGHU, J. VIROL., vol. 75, 2001, pages 809 - 20
DAS ET AL., J. VIROL., vol. 81, 2007, pages 7742 - 8
DAS ET AL., JOURNAL OF VIROLOGY, vol. 73, 1999, pages 81 - 91
DE LA PENA, M., EMBO J., vol. 22, no. 20, 2003, pages 5561 - 70
DEGLON, HUMAN GENE THERAPY, vol. 11, 2000, pages 179 - 90
DEVEREUX ET AL., NUCLEICACIDS RESEARCH, vol. 12, 1984, pages 387
DICKINS ET AL., NATURE GENETICS, vol. 37, 2005, pages 1281 - 1288
EMI ET AL., JOURNAL OF VIROLOGY, vol. 65, 1991, pages 1202 - 1207
FARRELL CM1WEST AGFELSENFELD G., MOL CELL BIOL., vol. 22, no. 11, June 2002 (2002-06-01), pages 3820 - 31
FEMS MICROBIOL LETT, vol. 177, no. 1, 1999, pages 187 - 50
FERREIRA, C., B., MOL THER METHODS CLIN DEV., vol. 17, 2019, pages 209 - 219
FIELDING ET AL., BLOOD, vol. 91, no. 5, 1998, pages 1802 - 1809
FLAJOLET, M. ET AL., J. VIROL., vol. 72, 1998, pages 6175 - 6180
GHATTAS, I.R. ET AL., MOL. CELL. BIOL., vol. 11, 1991, pages 5848 - 5859
GILMARTIN ET AL., GENES DEV., vol. 9, 1995, pages 72 - 83
HU ET AL., GENE THER, vol. 25, 2018, pages 454 - 472
HU, P., GENE THER., vol. 25, no. 7, October 2018 (2018-10-01), pages 454 - 472
HUM GENE THER, vol. 9, pages 1939 - 1950
IWAKUMA ET AL., VIROL, vol. 261, 1999, pages 120 - 32
J ELLIS ET AL., EMBO J., vol. 15, no. 3, 1 February 1996 (1996-02-01), pages 562 - 568
J. M. POLAKJAMES O'D. MCGEE: "Situ Hybridization: Principles and Practice", 1990, OXFORD UNIVERSITY PRESS
J. SAMBROOKE. F. FRITSCHT. MANIATIS: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
JANG ET AL., ENZYME, vol. 44, 1990, pages 292 - 309
JIMENEZ, R., M. ET AL.: "Trends in biochemical sciences vol.", CHEMISTRY AND BIOLOGY OF SELF-CLEAVING RIBOZYMES, vol. 40, no. 11, 2015, pages 648 - 661
KAMMLER, S. ET AL., RNA, vol. 7, no. 3, 2001, pages 421 - 434
KANG ET AL., J. VIROL., vol. 76, 2002, pages 9378 - 9388
KAYE ET AL., J VIROL., vol. 69, no. 10, 1995, pages 6588 - 92
KHARYTONCHYK ET AL., PROC. NATL. ACAD. SCI. USA., vol. 113, 2016, pages 13378 - 13383
KLASENS ET AL., NUCLEIC ACIDS RES., vol. 27, 1999, pages 446 - 54
KOTTERMAN, M.A.SCHAFFER, D.V., NAT. REV. GENET., vol. 15, 2014, pages 445 - 451
KUMAR MBRADOW BPZIMMERBERG J, HUM GENE THER., vol. 14, no. 1, 2003, pages 67 - 77
LEWIS ET AL., EMBO J, vol. 11, no. 8, 1992, pages 3053 - 3058
LUBELSKY ET AL., EMBO J., vol. 40, 2021, pages e106357
LUBELSKYULITSKY, NATURE, vol. 555, 2018, pages 107 - 111
LUND ET AL., J. BIOL. CHEM., vol. 259, 1984, pages 2013 - 2021
LUTZELBERGER; M. ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, pages 18644 - 18651
MACEJAKSARNOW, NATURE, vol. 353, 1991, pages 91
MAETZIG ET AL., GENE THER., vol. 17, no. 3, 2010, pages 400 - 411
MARTARANO ET AL., J VIROL, vol. 68, no. 5, 1994, pages 3102 - 3111
MARTY ET AL., BIOCHIMIE, vol. 72, 1990, pages 885 - 7
MAUNDER ET AL., NAT COMMUN., vol. 27, 2017, pages 8
MAURY ET AL., VIROLOGY, vol. 200, no. 2, 1994, pages 632 - 642
MIYAGWA ET AL., RNA, vol. 18, 2012, pages 738 - 751
MOL BIOL, vol. 49, no. 3, May 2015 (2015-05-01), pages 472 - 81
MORGAN, R.A.KAKARLA, S., CANCER J., vol. 20, 2014, pages 145 - 150
MORIARITY ET AL., NUCLEIC ACIDS RES., vol. 41, no. 8, April 2013 (2013-04-01), pages e92
MOUNTFORDSMITH, TIG, vol. 11, 1985, pages 179 - 184
MOUNTFORDSMITH, TIG, vol. 11, no. 5, May 1995 (1995-05-01), pages 179 - 184
MUHLEBACH, M.D. ET AL., RETROVIRUSES: MOLECULAR BIOLOGY, GENOMICS AND PATHOGENESIS, vol. 13, 2010, pages 347 - 370
NAVIAUX ET AL., J. VIROL., vol. 70, 1996, pages 2581 - 5
NILSON ET AL., GENE THER, vol. 3, no. 4, 1996, pages 280 - 286
PAZARENTZOS, E.MAZARAKIS, N.D., ADV. EXP. MED BIOL., vol. 818, 2014, pages 255 - 280
PELLETIERSONENBERG, NATURE, vol. 334, 1988, pages 320 - 325
POLING ET AL., RNA BIOL., vol. 14, 2017, pages 1570 - 1579
PROUDFOOT, GENES & DEV., vol. 25, 2011, pages 1770 - 1782
RALPH ET AL., NAT. MEDICINE, vol. 11, 2005, pages 429 - 433
RUNKEL, L. ET AL., VIROLOGY, vol. 194, no. 2, 1993, pages 530 - 536
SCHAMBACH ET AL., MOLECULAR THERAPY, vol. 15, 2007, pages 1167 - 1173
SERTKAYA, H. ET AL., SCI REP, vol. 11, 2021, pages 12067
STEWART HJFONG-WONG LSTRICKLAND ICHIPCHASE DKELLEHER MSTEVENSON LTHOREE VMCCARTHY JRALPH GSMITROPHANOUS KA, HUM GENE THER. MAR, vol. 22, no. 3, 2011, pages 357 - 69
STEWART, H. J.M. A. LEROUX-CARLUCCIC. J. SIONK. A. MITROPHANOUSP. A. RADCLIFFE, GENE THER. JUN, vol. 16, no. 6, 2009, pages 805 - 14
TAKAGAKIMANLEY, MOLECULAR AND CELLULAR BIOLOGY, vol. 17, 1997, pages 3907 - 3914
TOUZOT, F. ET AL., EXPERT OPIN. BIOL. THER., vol. 14, 2014, pages 789 - 798
UCHIDA, N. ET AL., NAT COMMUN, vol. 10, 2019, pages 4479
VALSESIA-WITTMAN ET AL., J VIROL, vol. 70, 1996, pages 2056 - 64
VAN DEN BERG ET AL., BIOCHIM BIOPHYS ACTA, vol. 1779, 2008, pages 668 - 677
VERMASOMIA, NATURE, vol. 389, no. 6648, 1997, pages 239 - 242
WEBB, C., H.LUPTAK, A., RNA BIOL., vol. 8, no. 5, 2011, pages 719 - 27
WEST, S., BIOCHEMICAL, vol. 40, 2012, pages 846 - 849
YANG ET AL., RETROVIROLOGY, vol. 4, 2007, pages 4
YANG, STRUCTURE, vol. 19, 2011, pages 368 - 377
YEE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9564 - 9568
YU ET AL., PNAS, vol. 83, 1986, pages 3194 - 98
ZHENG, Y.W. ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 22593 - 8
ZHONG, G., NAT BIOTECHNOL., vol. 38, no. 2, 2020, pages 169 - 175
ZUFFEREY, R. ET AL., J. VIROL., vol. 73, 1999, pages 2886 - 92

Also Published As

Publication number Publication date
US20250034589A1 (en) 2025-01-30
JP2024536908A (ja) 2024-10-08
WO2023062367A1 (en) 2023-04-20
EP4416296A1 (en) 2024-08-21
CN118234868A (zh) 2024-06-21
KR20240126856A (ko) 2024-08-21
EP4530355A2 (en) 2025-04-02
EP4530355A3 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
GB201800903D0 (en) Vectors
SG11202001367QA (en) Retroviral vectors
IL326027A (en) Lentiviral vector formulations
GB202010009D0 (en) Vector
GB2590774B (en) Vector
GB202019108D0 (en) Vector
GB201913974D0 (en) Vector
GB202114532D0 (en) Lentiviral Vectors
GB202114528D0 (en) Lentiviral vectors
GB202205606D0 (en) Lentiviral vector
SG11202102012SA (en) Improved lentiviral vector
IL316172A (en) Lentiviral vector
IL308705A (en) LENTIVIRAL vector
GB201906283D0 (en) Vector
GB202114530D0 (en) Retroviral vectors
GB202003711D0 (en) Lentiviral vectors
GB202003710D0 (en) Lentiviral vectors
GB202003709D0 (en) Lentiviral vectors
GB202214990D0 (en) Lentiviral vector
GB202214973D0 (en) Lentiviral vector
GB202205608D0 (en) Lentiviral vector
GB202205615D0 (en) Lentiviral vector
IL304808A (en) Retroviral vectors
HK40086276A (en) Lentiviral vectors
GB202019084D0 (en) Retroviral vectors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)